Amedeo Smart

Free Medical Literature Service

 

Amedeo

Bladder Cancer
  Free Subscription

Articles published in
Anticancer Res
    June 2025
  1. MATSUO T, Miyata Y, Harada J, Itoh I, et al
    Efficacy of Pembrolizumab as Second or Third-line Therapy for Local Advanced and Metastatic Urothelial Cancer.
    Anticancer Res. 2025;45:2563-2573.
    >> Share

  2. ONISHI T, Sekito S, Shibahara T, Yabana T, et al
    Randomized Study of Short-time Continuous Saline Irrigation After Transurethral Resection in Non-muscle Invasive Bladder Cancer.
    Anticancer Res. 2025;45:2653-2660.
    >> Share

    May 2025
  3. FURUBAYASHI N, Mochida M, Kijima A, Fujimoto Y, et al
    Treatment Outcomes After Progression With Enfortumab Vedotin in Patients With Advanced Urothelial Carcinoma.
    Anticancer Res. 2025;45:2185-2193.
    >> Share

  4. TUNG CH, Lin SH, Chang KP, Xu YW, et al
    Light Bladder Net: Non-invasive Bladder Cancer Prediction by Weighted Deep Learning Approaches and Graphical Data Transformation.
    Anticancer Res. 2025;45:1953-1964.
    >> Share

    March 2025
  5. YAMAGUCHI N, Morizane S, Yamane H, Shimizu R, et al
    Perioperative and Oncologic Outcomes of Robot-assisted Versus Laparoscopic Radical Cystectomy in Patients With Bladder Cancer.
    Anticancer Res. 2025;45:1215-1224.
    >> Share

    December 2024
  6. JARADAT JH, Idrissi YA, Saeed A
    HOOK3 Amplification in Bladder Urothelial Carcinoma: Insights from Gene Expression and Survival Analysis.
    Anticancer Res. 2024;44:5175-5185.
    >> Share

    October 2024
  7. DIONESE M, Bimbatti D, Pierantoni F, Lai E, et al
    Systemic Inflammation Indexes and Risk of Immune-related Adverse Events in Patients With Metastatic Urothelial Carcinoma Treated With Immunotherapy.
    Anticancer Res. 2024;44:4379-4386.
    >> Share

    September 2024
  8. SATO M, Sato T, Hozumi C, Han Q, et al
    [(11)C]Methionine PET vs. [(18)F]Fluorodeoxyglucose PET Whole-body Imaging to Determine the Extent of Methionine-addiction Compared to Glucose-addiction of Primary and Metastatic Cancer of the Trunk in Patients.
    Anticancer Res. 2024;44:3891-3898.
    >> Share

    August 2024
  9. ZEKAN D, Hogan T, Jackson B, Jackson G, et al
    The Novel Platinum Analog Dicycloplatin Provides Reliable Growth Inhibition of Urothelial Carcinoma Cells In Vitro.
    Anticancer Res. 2024;44:3243-3254.
    >> Share

    May 2024
  10. CHEN CH, Chen YC, Chang YC, Hung CH, et al
    Taurine Rescues Cancer-induced Atrophy in Human Skeletal Muscle Cells via Ameliorating the Inflammatory Tumor Microenvironment.
    Anticancer Res. 2024;44:1963-1971.
    >> Share

  11. KOBATAKE K, Ikeda K, Kohada Y, Tasaka R, et al
    Muscle-Invasive Bladder Cancer With Hydronephrosis Exhibits a High Frequency of Mutations in Fibroblast Growth Factor Receptor 3 Gene.
    Anticancer Res. 2024;44:1947-1954.
    >> Share

  12. HUBER F, Wolf I, Storz J, Schultze-Seemann S, et al
    Antibody-dye Conjugates Targeting EGFR and HER2 for the Photoimmunotherapy of Bladder Cancer.
    Anticancer Res. 2024;44:1837-1844.
    >> Share

  13. FUKUOKAYA W, Akazawa K, Kimura T
    Association Between Serum Magnesium Levels and Outcomes of Atezolizumab in Patients With Metastatic Urothelial Carcinoma.
    Anticancer Res. 2024;44:2117-2123.
    >> Share

  14. FUCHIZAWA H, Ando K, Motoi N, Iizuka T, et al
    STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-gamma-induced Apoptosis in Urothelial Cancer.
    Anticancer Res. 2024;44:1925-1930.
    >> Share

    April 2024
  15. SATO R, Watanabe K, Matsushita Y, Watanabe H, et al
    Assessment of Therapeutic Effects of Combined Treatment With Cisplatin and Anti-mouse Programmed Death (PD)-1 Antibody in a Mouse Urothelial Cancer Model.
    Anticancer Res. 2024;44:1417-1423.
    >> Share

  16. FURUBAYASHI N, Minato A, Tomoda T, Hori Y, et al
    Change in the Neutrophil-to-Eosinophil Ratio After Avelumab Maintenance for Advanced Urothelial Carcinoma: The UROKYU Study.
    Anticancer Res. 2024;44:1675-1681.
    >> Share

    March 2024
  17. YU SH, Wang CY, Wang SS, Li JR, et al
    Comparing Clinical Efficacy of Different Bacillus Calmette-Guerin Strains in Patients With T1 High Grade Bladder Cancer.
    Anticancer Res. 2024;44:1299-1307.
    >> Share

  18. SHINDO T, Hashimoto K, Takahashi A, Miyamoto S, et al
    Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy.
    Anticancer Res. 2024;44:1271-1279.
    >> Share

    February 2024
  19. ONER M, Lin E, Chiu KY, Chen MC, et al
    p35/CDK5 Regulates Bladder Cancer Proliferation and Migration and Promotes Higher Tumor Grade and Poor Survival Rate in Patients With Bladder Cancer.
    Anticancer Res. 2024;44:543-553.
    >> Share

    December 2023
  20. FURUBAYASHI N, Minato A, Tomoda T, Hori Y, et al
    Organ-specific Tumor Response to Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma: A Multicenter Retrospective Study.
    Anticancer Res. 2023;43:5689-5698.
    >> Share

    November 2023
  21. NISHIYAMA N, Kita Y, Ito K, Kato M, et al
    Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in Treatment Outcomes According to the Primary Site.
    Anticancer Res. 2023;43:5041-5050.
    >> Share

    October 2023
  22. SOMMER U, Grosser M, Aust D, Joehrens K, et al
    PD-L1 mRNA Detection in Immunohistochemically Negative Patients: A Complementary Method for a Better Treatment Selection?
    Anticancer Res. 2023;43:4365-4371.
    >> Share

    September 2023
  23. MINATO A, Kimuro R, Ohno D, Tanigawa K, et al
    Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World.
    Anticancer Res. 2023;43:4055-4060.
    >> Share

  24. KASHIWAGI E, Shiota M, Inokuchi J, Tsukahara S, et al
    Comparison of Testosterone Level of Seminal Vesicle Fluid in Patients With Prostate Cancer Versus Other Malignancies.
    Anticancer Res. 2023;43:4249-4254.
    >> Share

    August 2023
  25. TACHIBANA M, Tsubouchi K, Fukuhara Y, Aoyagi C, et al
    Factors Related to Overactive Bladder-like Symptoms in Bladder Cancer.
    Anticancer Res. 2023;43:3607-3613.
    >> Share

  26. ARAI T, Sazuka T, Oka R, Tsukamoto R, et al
    Investigation on the Usefulness of Photodynamic Diagnosis-assisted Targeted Bladder Biopsy: Japanese Real-world Study.
    Anticancer Res. 2023;43:3615-3621.
    >> Share

    May 2023
  27. SANO T, Aizawa R, Ito K, Nakamura K, et al
    Efficacy and Tolerability of Second-line Pembrolizumab With Radiation Therapy in Advanced Urothelial Carcinoma.
    Anticancer Res. 2023;43:2119-2126.
    >> Share

    April 2023
  28. YAMAGUCHI N, Morizane S, Yumioka T, Shimizu R, et al
    Effect of Adjuvant Systemic Chemotherapy on Intravesical Recurrence After Radical Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma.
    Anticancer Res. 2023;43:1725-1730.
    >> Share

  29. LUZHA J, Nass N, Czapiewski P, Schroeder N, et al
    Expression of Eukaryotic Translation Initiation Factors in the Urothelial Carcinoma of the Bladder.
    Anticancer Res. 2023;43:1437-1448.
    >> Share

  30. LEE YH, Wu RC, Mai HC, Huang WL, et al
    The Regulatory Role of Nuclear Respiratory Factor 1 in Bladder Cancer Cells.
    Anticancer Res. 2023;43:1521-1531.
    >> Share

    March 2023
  31. CHEN SY, Chao CN, Huang HY, Zhao PW, et al
    Artesunate Exhibits Synergy With Cisplatin and Cytotoxicity for Upper Tract and Bladder Urothelial Carcinoma Cells.
    Anticancer Res. 2023;43:1175-1184.
    >> Share

  32. LI JR, Wang SS, Lu K, Chen CS, et al
    First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study.
    Anticancer Res. 2023;43:1331-1339.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016